Shire's intrathecal ERT misses in MPS II trial

Shire plc (LSE:SHP; NASDAQ:SHPG) reported top-line data showing that intrathecal idursulfase (SHP609; formerly HGT-2310) missed the primary endpoint in the Phase II/III HGT-HIT-094 trial to treat pediatric patients

Read the full 281 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE